Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries

Leblebicioglu, Hakan; Arends, Joop; Ozaras, Reşat; Corti, Giampaolo; Santos, Lurdes; Boesecke, Christoph; Ustianowski, Andrew; Duberg, Ann-Sofi; Ruta, Simona; Salkic, Nermin; Husa, Petr; Lazarevic, Ivana; Pinede, Juan; Pshenichnaya, Natalia; Tsertswadze, Tengiz; Maticic, Mojca; Puca, Edmond; Abuova, Gulzhan; Gervain, Judit; Bayramli, Ramin; Ahmeti, Salih; Koulentaki, Mairi; Kilani, Badreddine; Vince, Adriana; Negro, Francesco; SÜNBÜL, MUSTAFA; Salmon, Dominique

doi:10.1016/j.antiviral.2017.12.001

Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries

Atıf İçin Kopyala

Leblebicioglu H., Arends J. E., Ozaras R., Corti G., Santos L., Boesecke C., ...Daha Fazla

ANTIVIRAL RESEARCH, cilt.150, ss.9-14, 2018 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 150
Basım Tarihi: 2018
Doi Numarası: 10.1016/j.antiviral.2017.12.001
Dergi Adı: ANTIVIRAL RESEARCH
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.9-14
İstanbul Üniversitesi Adresli: Hayır

Özet

Background. Treatment with direct acting antiviral agents (DAAs) has provided sustained virological response rates in > 95% of patients with chronic hepatitis C virus (HCV) infection. However treatment is costly and market access, reimbursement and governmental restrictions differ among countries. We aimed to analyze these differences among European and Eurasian countries.